PURE Bioscience (OTCMKTS:PURE) Short Interest Update

Posted by Tyrone Williams on Aug 17th, 2026

PURE Bioscience (OTCMKTS:PURE – Get Free Report) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totaling 7,738 shares, a growth of 100.2% from the July 15th total of 3,865 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 32,276 shares, the short-interest ratio is currently 0.2 days.

PURE Bioscience Price Performance

OTCMKTS PURE opened at $0.08 on Monday. The stock has a market cap of $10.40 million, a PE ratio of -2.67 and a beta of 0.21. PURE Bioscience has a fifty-two week low of $0.04 and a fifty-two week high of $0.14. The business has a 50 day moving average price of $0.07 and a two-hundred day moving average price of $0.07.

PURE Bioscience (OTCMKTS:PURE – Get Free Report) last issued its quarterly earnings data on Monday, June 15th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business had revenue of $0.51 million for the quarter.

PURE Bioscience Company Profile

(Get Free Report)

PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions.